CWP
CRL icon

Clark Wealth Partners’s Charles River Laboratories CRL Stock Holding History

Clark Wealth Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681 Hold
3
– – ﹤0.01% 515
2026
Q1 		$518 Hold
3
– – ﹤0.01% 561
2025
Q4 		$598 Hold
3
– – ﹤0.01% 521
2025
Q3 		$598 Hold
3
– – ﹤0.01% 521
2025
Q2 		$455 Buy
+3
New +$400 ﹤0.01% 492

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Clark Wealth Partners's CRL Position: Q2 2026 in Review

Clark Wealth Partners held its Charles River Laboratories (CRL) position steady in Q2 2026 at 3 shares worth $681. The position accounts for ﹤0.01% of the portfolio, ranked #515.

Clark Wealth Partners first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. 531 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Clark Wealth Partners held 3 shares of Charles River Laboratories worth $681 as of Q2 2026.
  • Clark Wealth Partners left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Clark Wealth Partners's portfolio in Q2 2026, its #515 holding.
  • Clark Wealth Partners first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • 531 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Clark Wealth Partners's 13F filing for Q2 2026, filed 28 Jul 2026.